GO:0004522 ribonuclease A activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004522 (ribonuclease A activity) describes the endonucleolytic cleavage of RNA to 3'-phosphomononucleotides and 3'-phosphooligonucleotides ending in C-P or U-P via 2',3'-cyclic phosphate intermediates.
• The term covers pancreatic ribonuclease A (RNase A) and related enzymes such as angiogenin, which share a catalytic mechanism but differ in biological roles.
• RNase A activity is not only a digestive enzyme; engineered variants can be cytotoxic to cancer cells and resistant to ribonuclease inhibitor.
• Surface adsorption, dimerization, and inhibitor binding are key regulatory mechanisms that modulate ribonuclease A activity in vitro and in vivo.
• Angiogenin, a member of the ribonuclease A superfamily, requires ribosomal RNA binding for activation, linking this activity to ribosome biology and stress responses.
• Studying GO:0004522 requires combining enzymatic assays, structural biology, and CRISPR-based models to dissect gene function and therapeutic potential.
Description
Ribonuclease A activity (GO:0004522) is a molecular function defined by the endonucleolytic cleavage of RNA to 3'-phosphomononucleotides and 3'-phosphooligonucleotides ending in C-P or U-P, proceeding through 2',3'-cyclic phosphate intermediates. This activity is best known from bovine pancreatic ribonuclease A (RNase A), a classic model enzyme that has been studied for decades as a paradigm for protein folding, catalysis, and inhibitor design. The term also encompasses related enzymes such as angiogenin, which share the catalytic mechanism but have distinct physiological roles in angiogenesis and ribosome regulation. For researchers, GO:0004522 provides a precise functional annotation that connects sequence, structure, and enzymatic behavior to cellular processes and disease. Understanding this activity is critical because it underlies RNA turnover, host defense, and emerging therapeutic strategies in oncology.
ribonuclease A activity At A Glance
| GO ID | GO:0004522 |
|---|---|
| GO term | ribonuclease A activity |
| Ontology | molecular_function |
| Synonym | RNase A activity; pancreatic ribonuclease activity; alkaline ribonuclease activity; ribonuclease I activity |
| Major function | Endonucleolytic cleavage of RNA to 3'-phosphomononucleotides and 3'-phosphooligonucleotides ending in C-P or U-P via 2',3'-cyclic phosphate intermediates |
| EC number | 3.1.27.5 (ribonuclease A) |
| Substrates | Single-stranded RNA, with preference for pyrimidine bases (C and U) |
| Products | 3'-phosphomononucleotides and 3'-phosphooligonucleotides ending in C-P or U-P |
| Cofactors | No metal ions required; histidine residues in the active site act as general acid/base catalysts |
| Inhibitors | Ribonuclease inhibitor (RI), a cytosolic protein that binds with high affinity; also affected by surface adsorption and curcumin |
What Is GO:0004522?
GO:0004522 describes the catalytic activity of enzymes that cut RNA internally, producing 3'-phosphomononucleotides and 3'-phosphooligonucleotides that end with cytidine (C-P) or uridine (U-P). The reaction proceeds via 2',3'-cyclic phosphate intermediates, meaning the enzyme first forms a cyclic phosphate on the RNA backbone and then hydrolyzes it to leave a 3'-phosphate product. This definition distinguishes ribonuclease A activity from other ribonucleases that generate different products or use different mechanisms.
Why Is ribonuclease A activity Important in Cell Biology?
Ribonuclease A activity is important because it is a fundamental RNA-processing function that influences RNA stability, gene expression, and cellular defense. Beyond its classic role in digestion, RNase A and its homologs are implicated in cancer therapy, angiogenesis, and host immunity. The enzyme's ability to degrade RNA makes it a potential anticancer agent when targeted to tumor cells, and its inhibitor interactions provide a model for understanding protein-protein regulation. Moreover, angiogenin, a ribonuclease A family member, is critical for ribosome biogenesis and stress responses, linking this activity to cell survival and proliferation. For researchers, GO:0004522 offers a well-defined functional handle to study enzyme mechanism, inhibitor design, and therapeutic applications.
• Provides a classic model for enzyme kinetics and protein folding studies.
• Underlies the cytotoxic activity of RNase A variants against cancer cells.
• Links to angiogenesis through angiogenin, a ribonuclease A homolog.
• Involved in host defense as an antimicrobial peptide enhancer.
• Regulated by ribonuclease inhibitor, affecting cellular RNA turnover.
• Surface adsorption can alter enzymatic activity, relevant for biosensors and biomaterials.
• Curcumin partially inhibits RNase A activity, suggesting dietary modulation.
• Angiogenin activation by the ribosome reveals a new layer of translational control.
• Dimerization can confer resistance to ribonuclease inhibitor, with antitumor implications.
• Serves as a target for CRISPR-based functional genomics to dissect RNA metabolism.
What Happens During ribonuclease A activity?
Substrate binding and orientation
In simple terms: The enzyme grabs a single-stranded RNA molecule and positions it for cutting.
Ribonuclease A binds single-stranded RNA with a preference for pyrimidine bases (cytosine and uracil). The active site cleft accommodates the RNA backbone, and specific subsites (B1, B2, P0, P1, P2) interact with the bases and phosphate groups to orient the scissile bond for cleavage. This binding step is reversible and can be influenced by surface adsorption, which may cause structural changes that alter activity.
Transphosphorylation to form 2',3'-cyclic phosphate
In simple terms: The enzyme cuts the RNA by first making a cyclic intermediate.
The catalytic mechanism involves two histidine residues (His12 and His119 in RNase A) that act as general acid and base. His12 deprotonates the 2'-hydroxyl group of the ribose, which then attacks the adjacent phosphate, forming a 2',3'-cyclic phosphate intermediate and releasing the 5'-hydroxyl end of the downstream RNA fragment. This transphosphorylation step is the first half of the reaction.
Hydrolysis of the cyclic intermediate
In simple terms: The cyclic intermediate is opened up by water to finish the cut.
In the second step, a water molecule hydrolyzes the 2',3'-cyclic phosphate, yielding a 3'-phosphomononucleotide or 3'-phosphooligonucleotide ending in C-P or U-P. His119 acts as a general base to activate water, while His12 protonates the leaving group. The final products are characteristic of ribonuclease A activity and distinguish it from other ribonucleases.
Product release and enzyme turnover
In simple terms: The cut RNA pieces are released, and the enzyme is ready to cut again.
After hydrolysis, the products diffuse away, and the enzyme returns to its initial state. The catalytic cycle can repeat multiple times. However, product inhibition or binding to inhibitors such as ribonuclease inhibitor (RI) can halt turnover. Additionally, dimerization of human pancreatic ribonuclease can confer resistance to RI, allowing continued activity in the presence of the inhibitor.
Regulation by inhibitor binding and dimerization
In simple terms: The enzyme can be switched off by a inhibitor protein or switched on by forming dimers.
Ribonuclease inhibitor (RI) is a cytosolic protein that binds to RNase A with femtomolar affinity, blocking its active site. This interaction is critical for protecting cellular RNA from uncontrolled degradation. Some RNase A variants, such as a dimer of human pancreatic ribonuclease, are resistant to RI and display antitumor activity. Thus, the balance between free and inhibited enzyme determines the level of ribonuclease A activity in cells.
Key Genes Involved in GO:0004522 ribonuclease A activity
The following genes and proteins are directly associated with ribonuclease A activity (GO:0004522) or its regulation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RNASE1 | Encodes pancreatic ribonuclease A, the archetypal enzyme for GO:0004522 | Model for enzyme mechanism, inhibitor design, and anticancer variants |
| RNASE2 | Encodes eosinophil-derived neurotoxin, a ribonuclease A family member | Roles in host defense and neurotoxicity; potential antiviral activity |
| RNASE3 | Encodes eosinophil cationic protein, a ribonuclease A homolog | Antimicrobial and cytotoxic activities; biomarker in asthma |
| RNASE4 | Encodes ribonuclease 4, involved in angiogenesis and lipid metabolism | Potential link to metabolic and vascular biology |
| RNASE6 | Encodes ribonuclease 6, expressed in monocytes and macrophages | Host defense and RNA degradation in immune cells |
| RNASE7 | Encodes ribonuclease 7, an antimicrobial peptide | Skin and urinary tract defense; potential therapeutic peptide |
| ANG | Encodes angiogenin, a ribonuclease A superfamily member that stimulates angiogenesis | Ribosome biogenesis, stress response, and cancer progression |
| RNH1 | Encodes ribonuclease inhibitor (RI), a cytosolic inhibitor of RNase A | Regulates RNA turnover and protects against cytotoxic RNases |
| RNASET2 | Encodes ribonuclease T2, a distinct family member with similar activity | Tumor suppressor and immune modulation |
| RNASEH1 | Encodes ribonuclease H1, which cleaves RNA in RNA-DNA hybrids | Distinct from RNase A but often studied in parallel for RNA metabolism |
| RNASEH2A | Encodes a subunit of ribonuclease H2, involved in genome stability | Mutations cause Aicardi-Goutières syndrome; not directly RNase A but related |
| DICER1 | Encodes a ribonuclease III enzyme that processes miRNA | RNA interference; not RNase A but shares RNA cleavage themes |
| XRN1 | Encodes a 5'-3' exoribonuclease, not RNase A but relevant to RNA turnover | RNA stability and decay pathways |
| EXOSC10 | Encodes an exosome component with 3'-5' exonuclease activity | RNA quality control; not RNase A but related to RNA degradation |
| POP1 | Encodes a protein subunit of RNase P and RNase MRP | tRNA processing; not RNase A but ribonuclease family |
| SLFN11 | Encodes Schlafen 11, a DNA/RNA helicase involved in replication stress | Not RNase A but often studied in cancer therapy resistance |
| TP53 | Encodes p53, a tumor suppressor that can regulate RNase A family genes | Indirect regulation of RNA metabolism and apoptosis |
| EGFR | Encodes epidermal growth factor receptor, a signaling protein | Not RNase A but often co-studied in cancer models |
How Is ribonuclease A activity Regulated?
Ribonuclease A activity is regulated at multiple levels. The most direct regulation is through ribonuclease inhibitor (RI), a cytosolic protein that binds with high affinity and blocks the active site, preventing uncontrolled RNA degradation. Dimerization of human pancreatic ribonuclease can confer resistance to RI, thereby increasing activity. Surface adsorption to solid surfaces can induce structural changes that either enhance or reduce enzymatic activity, depending on the surface chemistry. Small molecules such as curcumin can partially inhibit RNase A activity, suggesting dietary or pharmacological modulation. Additionally, angiogenin, a ribonuclease A homolog, is activated by binding to ribosomal RNA, linking its activity to ribosome biogenesis and stress responses. These regulatory mechanisms ensure that ribonuclease A activity is tightly controlled in cells.
ribonuclease A activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RNASE1 | Cancer; antitumor activity of RNase A variants | Knockout of RNASE1 in cancer cell lines; overexpression of cytotoxic variants |
| ANG | Angiogenesis; amyotrophic lateral sclerosis (ALS) | Knock-in of ALS-associated ANG mutations in iPSCs; angiogenin overexpression |
| RNH1 | Regulation of RNA turnover; cancer resistance | Knockout of RNH1 to sensitize cells to RNase A cytotoxicity |
| RNASE7 | Antimicrobial defense; skin infections | Overexpression of RNASE7 in keratinocytes; antimicrobial assays |
| RNASE2 | Host defense; neurotoxicity | Knockout in immune cells; neurotoxicity assays |
Cancer
Ribonuclease A activity has been harnessed for anticancer therapy. Engineered RNase A variants with potent cytotoxic activity can degrade RNA in tumor cells, leading to cell death. A ribonuclease inhibitor-resistant dimer of human pancreatic ribonuclease displays specific antitumor activity, suggesting that evading RI is a strategy for therapeutic development. Angiogenin, a ribonuclease A family member, promotes angiogenesis and is upregulated in various cancers, contributing to tumor growth and metastasis.
Angiogenesis and vascular biology
Angiogenin (ANG) is a ribonuclease A homolog that stimulates blood vessel formation. Replacing a surface loop of RNase A endows it with angiogenic activity, demonstrating that subtle structural changes can switch biological function. Angiogenin activation by the ribosome is essential for its angiogenic and ribosome biogenesis roles, linking ribonuclease A activity to vascular development and tissue repair.
Host defense and antimicrobial activity
Several ribonuclease A family members, such as RNASE7 and eosinophil cationic protein, exhibit antimicrobial activity against bacteria and fungi. Bovine pancreatic ribonuclease A enhances the activity of antimicrobial peptides HNP1 and LL-37, suggesting a cooperative role in innate immunity. This positions ribonuclease A activity as a component of host defense beyond RNA degradation.
Neurodegeneration and ribosomopathies
Angiogenin mutations have been linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, through impaired ribosome biogenesis and stress granule formation. While direct links between RNase A activity and neurodegeneration are less established, the ribosome-related functions of angiogenin highlight the importance of this activity in neuronal survival.
From ribonuclease A activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does RNASE1 knockout reduce cellular RNA degradation? | CRISPR knockout of RNASE1 in HeLa or HEK293 cells |
| Can point mutations in the active site abolish ribonuclease A activity? | CRISPR point mutation of catalytic histidines (H12A, H119A) in RNASE1 |
| Does knock-in of a ribonuclease inhibitor-resistant dimer enhance antitumor activity? | CRISPR knock-in of dimerizing mutations in RNASE1 in cancer cells |
| What is the effect of angiogenin overexpression on angiogenesis? | CRISPR overexpression of ANG in endothelial cells; tube formation assays |
| How does ribonuclease inhibitor (RNH1) regulate RNase A activity? | CRISPR knockout of RNH1; measure RNase A activity and RNA integrity |
| Can tagged knock-in of RNASE1 reveal its subcellular localization? | CRISPR knock-in of GFP or FLAG tag at the RNASE1 locus |
How to Study the ribonuclease A activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNase activity assay with yeast RNA | Acid-soluble nucleotide release | Screening for inhibitors or activators of RNase A |
| Cytidine 2',3'-cyclic monophosphate hydrolysis | Catalytic rate of cyclic phosphate cleavage | Kinetic characterization of RNase A variants |
| X-ray crystallography | Three-dimensional structure of enzyme-substrate complexes | Mechanistic studies of catalytic residues |
| Surface plasmon resonance | Binding affinity between RNase A and inhibitors | Quantifying ribonuclease inhibitor interaction |
| CRISPR knockout | Loss-of-function phenotype | Determining gene essentiality for RNase A activity |
| CRISPR knock-in | Introduction of specific mutations or tags | Modeling disease-associated variants or tracking localization |
| RNA-seq | Transcriptome-wide RNA levels | Assessing RNA degradation upon RNase A modulation |
| Ribo-seq | Ribosome occupancy and translation efficiency | Studying angiogenin's role in translation |
Enzymatic activity assays
Ribonuclease A activity is commonly measured using synthetic substrates such as cytidine 2',3'-cyclic monophosphate or yeast RNA. The release of acid-soluble nucleotides is quantified spectrophotometrically at 260 nm. These assays are used to assess enzyme kinetics, inhibitor effects (e.g., curcumin), and the impact of surface adsorption.
Structural biology and biophysics
X-ray crystallography and NMR spectroscopy have provided detailed snapshots of RNase A in complex with substrates and inhibitors. These methods reveal the catalytic mechanism, including the roles of His12 and His119, and the conformational changes induced by inhibitor binding. Surface plasmon resonance and isothermal titration calorimetry measure binding affinities, such as the interaction between RNase A and ribonuclease inhibitor.
CRISPR-based functional genomics
CRISPR knockout, point mutation, and knock-in models enable precise dissection of gene function in the context of ribonuclease A activity. For example, knockout of RNASE1 can reveal its contribution to RNA turnover, while knock-in of catalytic dead mutants can separate enzymatic activity from non-catalytic functions. Pooled CRISPR screens can identify modifiers of RNase A sensitivity.
RNA sequencing and Ribo-seq
RNA-seq measures global changes in RNA abundance and stability upon modulation of ribonuclease A activity. Ribo-seq provides ribosome footprinting to assess translation efficiency and ribosome stalling, particularly relevant for angiogenin, which binds ribosomal RNA. These methods link enzymatic activity to transcriptome-wide effects.
How CRISPR Can Be Used to Study GO:0004522 ribonuclease A activity
Knockout
CRISPR knockout of RNASE1 or other ribonuclease A family genes can abolish enzymatic activity, allowing researchers to study loss-of-function phenotypes such as altered RNA stability, cell viability, and stress responses. Knockout of RNH1, the ribonuclease inhibitor, can sensitize cells to RNase A cytotoxicity, revealing regulatory networks.
Point Mutation
CRISPR point mutation can introduce catalytic dead mutations (e.g., H12A, H119A) into RNASE1 to separate enzymatic activity from non-catalytic functions. This is crucial for understanding whether observed phenotypes depend on RNA cleavage. Point mutations can also model disease-associated variants in ANG.
Knock-in
CRISPR knock-in enables the introduction of specific sequences, such as dimerizing mutations that confer ribonuclease inhibitor resistance, or tags for localization studies. Knock-in of a dimeric RNase A variant can enhance antitumor activity in cancer models. Tagged knock-in of RNASE1 allows real-time tracking of enzyme localization and secretion.
Overexpression
CRISPR overexpression (e.g., via CRISPRa) can drive high-level expression of RNASE1 or ANG to study their effects on cell proliferation, angiogenesis, and RNA metabolism. Overexpression of angiogenin in endothelial cells promotes tube formation, linking ribonuclease A activity to angiogenesis.
How EDITGENE Supports ribonuclease A activity Research
Researchers studying ribonuclease A activity-related genes often need to determine whether a candidate gene is causally involved in RNA metabolism, cancer, or host defense. This requires precise genetic models that can knockout, mutate, knock-in, or overexpress the gene of interest. EDITGENE provides end-to-end CRISPR services to generate such models, coupled with functional validation and bioinformatics.
Contact EDITGENE today to design your custom CRISPR model for ribonuclease A activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| RNASE2 Knockout HEK293 Cell Line | EDJ-KQ5677 | Human | 6036 | Details Get a Quote |
| RNASE8 Knockout HEK293 Cell Line | EDJ-KQ8159 | Human | 122665 | Details Get a Quote |
| RNASE1 Knockout HEK293 Cell Line | EDJ-KQ15088 | Human | 6035 | Details Get a Quote |
| RNASE1 Knockout A-549 Cell Line | EDJ-KQ45661 | Human | 6035 | Details Get a Quote |
| RNASE1 Knockout HCT 116 Cell Line | EDJ-KQ45662 | Human | 6035 | Details Get a Quote |
| RNASE1 Knockout THP-1 Cell Line | EDJ-KZ432 | Human | 6035 | Details Get a Quote |
| RNASE4 Knockout HEK293 Cell Line | EDJ-KQ50569 | Human | 6038 | Details Get a Quote |
| RNASE1 Knockout HeLa Cell Line | EDJ-KQ54328 | Human | 6035 | Details Get a Quote |
| RNASE2 Knockout HeLa Cell Line | EDJ-KQ54329 | Human | 6036 | Details Get a Quote |
| RNASE4 Knockout HeLa Cell Line | EDJ-KQ54331 | Human | 6038 | Details Get a Quote |
| RNASE8 Knockout HeLa Cell Line | EDJ-KQ58103 | Human | 122665 | Details Get a Quote |
| RNASE2 Knockout A-549 Cell Line | EDJ-KQ62822 | Human | 6036 | Details Get a Quote |
| RNASE4 Knockout A-549 Cell Line | EDJ-KQ62824 | Human | 6038 | Details Get a Quote |
| RNASE8 Knockout A-549 Cell Line | EDJ-KQ66591 | Human | 122665 | Details Get a Quote |
| RNASE2 Knockout HCT 116 Cell Line | EDJ-KQ71287 | Human | 6036 | Details Get a Quote |
Frequently Asked Questions About ribonuclease A activity
What is ribonuclease A activity?
Ribonuclease A activity (GO:0004522) is the endonucleolytic cleavage of RNA to 3'-phosphomononucleotides and 3'-phosphooligonucleotides ending in C-P or U-P via 2',3'-cyclic phosphate intermediates.
What genes are involved in ribonuclease A activity?
Key genes include RNASE1 (pancreatic ribonuclease A), ANG (angiogenin), RNH1 (ribonuclease inhibitor), and other RNASE family members such as RNASE2, RNASE3, RNASE4, RNASE6, and RNASE7.
What is the function of RNase A?
RNase A degrades single-stranded RNA, playing roles in digestion, host defense, and RNA turnover. Engineered variants can be cytotoxic to cancer cells.
How is ribonuclease A activity regulated?
It is regulated by ribonuclease inhibitor (RI), dimerization, surface adsorption, and small molecules like curcumin.
What diseases are associated with ribonuclease A activity?
Cancer, angiogenesis-related disorders, and neurodegenerative diseases such as ALS (via angiogenin) are linked to this activity.
How can I study ribonuclease A activity in the lab?
Common methods include enzymatic assays with yeast RNA or cyclic nucleotides, structural biology, and CRISPR-based knockout or knock-in models.
What is the role of angiogenin in ribonuclease A activity?
Angiogenin is a ribonuclease A homolog that stimulates angiogenesis and is activated by ribosomal RNA, linking this activity to ribosome biogenesis.
Can CRISPR be used to study ribonuclease A activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of gene function in this pathway.
What is the difference between RNase A and RNase H?
RNase A cleaves single-stranded RNA, while RNase H specifically degrades RNA in RNA-DNA hybrids. They are distinct enzymes with different GO terms.
How does curcumin affect ribonuclease A activity?
Curcumin partially inhibits RNase A activity, as shown by fluorescence spectroscopy and theoretical studies.
Conclusion
Ribonuclease A activity (GO:0004522) is a well-defined molecular function with broad biological significance, from RNA turnover and host defense to angiogenesis and cancer therapy. The catalytic mechanism, involving 2',3'-cyclic phosphate intermediates, is a classic example of enzyme action. Key genes such as RNASE1, ANG, and RNH1 are central to this activity, and their dysregulation contributes to diseases including cancer and ALS. CRISPR-based models offer powerful tools to dissect these functions, and EDITGENE provides comprehensive services to accelerate such research.
References
- 1. Sahoo BK et al.. 2024. Assessing Partial Inhibition of Ribonuclease A Activity by Curcumin through Fluorescence Spectroscopy and Theoretical Studies.. J Fluoresc 34(6):2641-2654 PMID: 37870732
- 2. Leland PA et al.. 1998. Ribonuclease A variants with potent cytotoxic activity.. Proc Natl Acad Sci U S A 95(18):10407-12 PMID: 9724716
- 3. Strydom DJ. 1998. The angiogenins.. Cell Mol Life Sci 54(8):811-24 PMID: 9760990
- 4. Raines RT et al.. 1995. Replacing a surface loop endows ribonuclease A with angiogenic activity.. J Biol Chem 270(29):17180-4 PMID: 7615514
- 5. Wei Y et al.. 2014. Adsorption-induced changes in ribonuclease A structure and enzymatic activity on solid surfaces.. Langmuir 30(49):14849-58 PMID: 25420087
- 6. Attery A et al.. 2018. A ribonuclease inhibitor resistant dimer of human pancreatic ribonuclease displays specific antitumor activity.. Int J Biol Macromol 107(Pt B):1965-1970 PMID: 29042278
- 7. Ericksen B. 2022. Enhancement of the activity of the antimicrobial peptides HNP1 and LL-37 by bovine pancreatic ribonuclease A.. F1000Res 11:933 PMID: 37360940
- 8. Loveland AB et al.. 2024. Structural mechanism of angiogenin activation by the ribosome.. Nature 630(8017):769-776 PMID: 38718836
